Evidence Review · 05
Established optical lineage. Contemporary hydrophobic platform.
A review of the direct HP evidence, from the FDA randomized trial to material-comparison studies. Functional range is considered alongside quality of vision, device handling and the limits of family-level evidence.
Burak Mergen, MD, FEBO, FICO
Ophthalmic Surgeon
Read opens the full PDF in a new tab.
The evidence review in one minute
Regulatory evidence
Distance BCDVA met prespecified non-inferiority; DCIVA at 66 cm and DCNVA at 40 cm met superiority criteria. Monofocal is the comparator, not a contemporary trifocal.
Review p. 05 · reference 1Quality of vision
Halos and starbursts were more frequent at 12 months. Night-driving difficulty moderately favoured monofocal; contrast differences were not clinically meaningful in the FDA assessment.
Review p. 06 · reference 1Material transition
Hydrophobic POD F GF was compared with hydrophilic POD F. Finite follow-up and attrition limit the long-term inference.
Review p. 07 · references 2–3Evidence boundaries
Longer-term outcomes, material-specific PCO/glistening implications and broad comparisons with current alternatives remain open. The FDA device-handling finding has a defined denominator and mitigation context.
Review pp. 08–10 · references 1, 4, 8OIE interpretation
FineVision HP is best understood as a hydrophobic implementation of an established trifocal optical design. The direct HP evidence now includes a substantial randomized regulatory trial. It supports functional range while documenting a measurable quality-of-vision trade-off.
The definitive full evidence review
Complete evidence, methods and references are in the PDF.
If your browser does not display the reader, open the PDF directly.
These declarations concern OIE and its author. They do not describe the funding or financial relationships of the studies reviewed.
Evidence appraised through 26 September 2026. Version 1.0. Later findings may change interpretation.